glp-1 headache Glucagon-like peptide-1 (GLP-1) receptor agonists for and pain disorders: a systematic review | The Journal of Headache and Pain GLP-1s as a potential migraine
Description
Is it possible to summarize the outcomes of that trial?
It's everywhere right now.
Recent signals underscore this shift: Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market capitalization [1] buoyed by global demand for obesity medications
New trial data for Amgen's GLP-1 drug MariTide shows a weight loss of 20 percent in non-diabetic participants with obesity or overweight.
A new deal may cut the cost of weight-loss drugs, but this UVA professor warns of potential long-term risks.
